Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 2:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cancer Cachexia Clear all
Completed Phase 3 Interventional

Etanercept in Treating Cancer-Related Cachexia and Anorexia in Patients With Advanced Cancer

NCT00046904
View directory record Official record
Conditions
Anorexia, Cachexia, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
etanercept
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
19
States / cities
Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated May 4, 2011 · Synced Sep 7, 2026, 2:50 AM EDT
Completed Phase 1 Interventional

Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS

NCT00000646
View directory record Official record
Conditions
HIV Infections
Interventions
Pentoxifylline
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
2
States / cities
Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 7, 2026, 2:50 AM EDT
Recruiting Phase 2 Interventional

Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy

NCT06937177
View directory record Official record
Conditions
Cancer Weight Loss
Interventions
TCMCB07, Placebo
Drug
Lead sponsor
Endevica Bio
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
25
States / cities
Tucson, Arizona • Los Angeles, California • Santa Monica, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 7, 2026, 2:50 AM EDT
Completed Not applicable Interventional

Acupuncture for Unintentional Weight Loss and Anorexia With GI Cancer

NCT02148159
View directory record Official record
Conditions
Malignant Neoplasm of Gastrointestinal Tract
Interventions
Cachexia Acupuncture-A (Peace Classic Needles® ), General Acupuncture-B (Peace Classic Needles®)
Device
Lead sponsor
University of Florida
Other
Eligibility
21 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Sep 7, 2026, 2:50 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer

NCT03637816
View directory record Official record
Conditions
Anorexia, Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Anamorelin Hydrochloride, Placebo, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 7, 2026, 2:50 AM EDT
Completed No phase listed Observational

Non-Invasive Assessment of Skeletal Muscle Loss in Cancer Patients - Phase II

NCT01694602
View directory record Official record
Conditions
Cachexia
Interventions
(non-radioactive) Oral deuterated 3-methylhistidine (D-3MH)
Biological
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Sep 7, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)

NCT01387282
View directory record Official record
Conditions
Cachexia, Non-Small Cell Lung Cancer
Interventions
Anamorelin HCl, Placebo
Drug
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Industry
Eligibility
18 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
14
States / cities
Corona, California • Fountain Valley, California • Glendale, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Sep 7, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT03743051
View directory record Official record
Conditions
Cachexia; Cancer, Non Small Cell Lung Cancer
Interventions
Anamorelin Hydrochloride, Placebo Oral Tablet
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
24
States / cities
Tucson, Arizona • Little Rock, Arkansas • Riverside, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 7, 2026, 2:50 AM EDT
Active, not recruiting No phase listed Observational

PET Avidity in Cachexia-Inducing Lung and Gastrointestinal Tumors

NCT03568019
View directory record Official record
Conditions
Cachexia; Cancer
Interventions
Retrospective study
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 7, 2026, 2:50 AM EDT
Terminated Phase 3 Interventional Results available

Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients

NCT00637728
View directory record Official record
Conditions
Anorexia, Cachexia, Weight Loss
Interventions
Megestrol acetate concentrated suspension 110 mg/mL, Placebo
Drug
Lead sponsor
Par Pharmaceutical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
3
States / cities
Miami, Florida • Cumberland, Maryland • Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Sep 7, 2026, 2:50 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss

NCT00219817
View directory record Official record
Conditions
Cancer Cachexia
Interventions
RC-1291 HCl
Drug
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
7
States / cities
Greenbrae, California • Boston, Massachusetts • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2013 · Synced Sep 7, 2026, 2:50 AM EDT
Terminated No phase listed Observational

Pilot Project for Cardiopulmonary and Functional Evaluation in Patients With Pancreatic Cancer Associated Cachexia

NCT02580422
View directory record Official record
Conditions
Cachexia, Pancreatic Cancer
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 7, 2026, 2:50 AM EDT
Completed Not applicable Interventional

Bovine Lactoferrin Supplement in Improving Taste in Patients With Cancer Receiving Chemotherapy

NCT01941810
View directory record Official record
Conditions
Anorexia, Cachexia, Malignant Neoplasm, Oral Complications of Chemotherapy
Interventions
bovine lactoferrin supplement, questionnaire administration, quality-of-life assessment, laboratory biomarker analysis
Dietary Supplement · Other · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Sep 7, 2026, 2:50 AM EDT
Completed Not applicable Interventional

Vitamin D for Muscle Metabolic Function in Cancer Cachexia

NCT03144128
View directory record Official record
Conditions
Cancer Cachexia, Vitamin D Deficiency
Interventions
Vitamin D, Placebo
Dietary Supplement
Lead sponsor
David Travis Thomas
Other
Eligibility
45 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Sep 7, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)

NCT01387269
View directory record Official record
Conditions
Cachexia, Non-Small Cell Lung Cancer
Interventions
Anamorelin HCl, Placebo
Drug
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
12
States / cities
Fullerton, California • Glendale, California • La Jolla, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Sep 7, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)

NCT01395914
View directory record Official record
Conditions
Cachexia, Non-Small Cell Lung Cancer
Interventions
Anamorelin HCl, Placebo
Drug
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Industry
Eligibility
18 Years and older
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
19
States / cities
Corona, California • Fountain Valley, California • Fullerton, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Sep 7, 2026, 2:50 AM EDT
Terminated Phase 2 Interventional Results available

The Role of Ghrelin in Cancer Cachexia

NCT01505764
View directory record Official record
Conditions
Cancer Cachexia
Interventions
Anamorelin HCl, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 7, 2026, 2:50 AM EDT
Recruiting Phase 2 Interventional

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

NCT05705492
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma, Advanced Esophageal Carcinoma, Metastatic Esophageal Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Esophageal Carcinoma, Locally Advanced Gastric Carcinoma, Metastatic Colorectal Carcinoma (mCRC), Advanced Lung Carcinoma, Locally Advanced Hepatocellular Carcinoma
Interventions
Olanzapine, Placebo Administration, Questionnaire Administration
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 7, 2026, 2:50 AM EDT
Completed No phase listed Observational

Evaluating Weight Stability of Pancreatic Cancer Cachexia Patients

NCT02400398
View directory record Official record
Conditions
Pancreatic Neoplasms, Pancreatic Cancer, Cachexia, Weight Loss
Interventions
Tube feeding
Other
Lead sponsor
Andrew Hendifar, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Sep 7, 2026, 2:50 AM EDT
Withdrawn Not applicable Interventional

The Role of Muscle Cachexia in Pancreatic Cancer

NCT02515513
View directory record Official record
Conditions
Pancreas Cancer
Interventions
Muscle Tissue Biopsy Sample
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 7, 2026, 2:50 AM EDT
Completed Phase 1 Interventional

Low Antioxidant Diet in Controlling Cachexia in Patients With Oropharyngeal Cancer Receiving Chemotherapy and Radiation Therapy

NCT00486304
View directory record Official record
Conditions
Cachexia, Head and Neck Cancer, Weight Changes
Interventions
ADD, Placebo
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2012 · Synced Sep 7, 2026, 2:50 AM EDT
Not yet recruiting Early Phase 1 Interventional

Feasibility Study for Repurposing RET Inhibitors

NCT07146893
View directory record Official record
Conditions
Cachexia-Anorexia Syndrome
Interventions
Selpercatinib, Strength Assessment
Drug · Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 7, 2026, 2:50 AM EDT
Completed Not applicable Interventional

Muscle Stimulation for Physical Function During Stem Cell Transplant

NCT04364256
View directory record Official record
Conditions
Autologous Hematopoietic Stem Cell Transplant
Interventions
RS-4i Plus Sequential Stimulator (RS Medical, Vancouver, WA)
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Sep 7, 2026, 2:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cancer-Associated Muscle Atrophy and Weakness: An Investigation of Etiology

NCT03012139
View directory record Official record
Conditions
Metastatic Cancer, Cachexia; Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2020 · Synced Sep 7, 2026, 2:50 AM EDT